argenx Stock Climbs on Expanded FDA Approval for VYVGART

FDA Broadens Approval for argenx's Myasthenia Gravis Treatment

The U.S. Food and Drug Administration has granted expanded approval for argenx's VYVGART and VYVGART Hytrulo, leading to a 3% rise in the company's shares during premarket trading. The decision broadens the treatment's use to include all adult patients diagnosed with generalized myasthenia gravis, or gMG.

A Landmark for gMG Treatment

This regulatory milestone establishes VYVGART as the first and only treatment approved for all adult gMG serotypes. The expansion now covers patients who are anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive, and triple seronegative. This is particularly crucial for the approximately 20% of gMG patients without detectable AChR antibodies, a group that has historically faced challenges in diagnosis and treatment.

Clinical Data and Market Impact

The approval is supported by positive data from the Phase 3 ADAPT SERON study. The trial successfully met its primary endpoint, demonstrating a statistically significant improvement in the Myasthenia Gravis Activities of Daily Living score for patients treated with VYVGART compared to a placebo. The treatment was reportedly well tolerated, with a safety profile consistent with previous studies. This expanded indication strengthens argenx's competitive position in the neurology market.

Summary and Outlook

The expanded FDA approval allows healthcare providers to prescribe VYVGART based on a clinical diagnosis of gMG, removing the barrier of antibody testing for treatment initiation. With ongoing development for other patient populations, including ocular and pediatric gMG, argenx is poised for continued growth in this therapeutic area. Investors will monitor the treatment's market adoption and its impact on the company's revenue.

FAQ

Q: What was the main announcement from the FDA regarding argenx?
A: The FDA expanded the approval for argenx's VYVGART and VYVGART Hytrulo to treat all adult patients with generalized myasthenia gravis, regardless of their antibody status.

Q: How did the market react to this news?
A: argenx (ARGX) shares rose 3% in premarket trading following the announcement.

Q: Why is this approval significant for gMG patients?
A: It provides an approved treatment option for the approximately 20% of gMG patients who do not have detectable AChR antibodies and previously faced diagnostic and management challenges.

Source: Investing.com